Quoin Pharmaceuticals Q4 2022 Earnings Report $0.32 -0.01 (-4.06%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Quoin Pharmaceuticals EPS ResultsActual EPS-$4.92Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AQuoin Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AQuoin Pharmaceuticals Announcement DetailsQuarterQ4 2022Date3/8/2023TimeN/AConference Call ResourcesQNRX Earnings History Quoin Pharmaceuticals Earnings HeadlinesQuoin Pharmaceuticals launches ‘NETHERTON NOW’ campaignFebruary 5, 2025 | markets.businessinsider.comQuoin Pharmaceuticals launches Netherton awareness campaignFebruary 4, 2025 | msn.comHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?February 23, 2025 | Behind the Markets (Ad)Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or CureFebruary 4, 2025 | globenewswire.comInsider Buyers At Quoin Pharmaceuticals Likely Disappointed With 13% SlideFebruary 2, 2025 | uk.finance.yahoo.comQuoin Pharmaceuticals: Buy Rating Affirmed Amidst Potential First-Mover Advantage in Netherton Syndrome TreatmentJanuary 25, 2025 | markets.businessinsider.comSee More Quoin Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Quoin Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quoin Pharmaceuticals and other key companies, straight to your email. Email Address About Quoin PharmaceuticalsQuoin Pharmaceuticals (NASDAQ:QNRX), a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.View Quoin Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)ONEOK (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Home Depot (2/25/2025)Public Storage (2/25/2025)Sempra (2/25/2025)NVIDIA (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
